CoChat

Standards for the development and methodology of the 2023 IWGDF guidelines

Open access
Bus, Sicco A., Monteiro‐Soares, Matilde, Game, Fran, van Netten, Jaap J., Apelqvist, Jan, Fitridge, Robert, Senneville, Eric, Schaper, Nicolaas C., IWGDF Editorial Board · 2024 · Diabetes/Metabolism Research and Reviews
Cited by 27

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Aims: Diabetes‐related foot disease is a major source of patient burden and societal costs. Investing in evidence‐based international guidelines on diabetes‐related foot disease is important to reduce this burden and costs, provided the guidelines are focused on outcomes important to key stakeholders and are evidence‐based and properly implemented. Materials and Methods: The International Working Group on the Diabetic Foot (IWGDF) has published and updated international guidelines since 1999. The 2023 updates were made using the Grading of Recommendations Assessment Development and Evaluation evidence‐to‐decision framework. This concerns formulating relevant clinical questions and important outcomes, conducting systematic reviews of the literature and meta‐analyses where appropriate, completing summary of judgement tables, and writing recommendations that are specific, unambiguous and actionable, along with their transparent rationale. Results: We herein describe the development of the 2023 IWGDF Guidelines on the prevention and management of diabetes‐related foot disease, which consists of seven chapters, each prepared by a separate working group of international experts. These chapters provide guidelines related to diabetes‐related foot disease on prevention; classification of diabetes‐related foot ulcer, offloading, peripheral artery disease, infection, wound healing interventions, and active Charcot neuro‐osteoarthropathy. Based on these seven guidelines, the IWGDF Editorial Board also produced a set of practical guidelines. Each guideline underwent extensive review by the members of the IWGDF Editorial Board as well as independent international experts in each field. Conclusions: We believe that the adoption and implementation of the 2023 IWGDF guidelines by healthcare providers, public health agencies, and policymakers will improve the prevention and management of diabetes‐related foot disease, and subsequently reduce the worldwide patient and societal burden caused by this disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/dmrr.3656

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 19

  1. International Diabetes Federation, 2021, IDF Diabetes Atlas
  2. 10.2337/dc19‐1614 · DOI · Paper page
  3. 10.1016/s0140‐6736(05)67698‐2 · DOI · Paper page
  4. 10.2337/dc06‐0306 · DOI · Paper page
  5. 10.1007/s00125‐008‐0940‐0 · DOI · Paper page
  6. 10.1002/dmrr.2245 · DOI · Paper page
  7. 10.1111/dme.14961 · DOI
  8. 10.1002/dmrr.3268 · DOI · Paper page
  9. 10.1136/bmj.i2089 · DOI · Paper page
  10. 10.1002/dmrr.2703 · DOI · Paper page
  11. 10.1186/1471‐2288‐3‐25 · DOI · Paper page
  12. 10.1001/jama.271.5.389 · doi:10.1001/jama.271.5.389 · Paper page
  13. 10.1001/jama.271.9.703 · doi:10.1001/jama.271.9.703 · Paper page
  14. 10.7326/0003‐4819‐158‐4‐201302190‐00009 · DOI · Paper page
  15. 10.7326/0003‐4819‐144‐6‐200603210‐00010 · DOI · Paper page
  16. 10.12968/jowc.2017.26.6.324 · DOI
  17. 10.1002/dmrr.2738 · DOI · Paper page
  18. 10.1016/j.diabres.2006.05.014 · DOI
  19. 10.1186/1475‐2840‐11‐18 · DOI

Cited by

See all 27

Metadata

Authors
Bus, S. A., Monteiro‐Soares, M., Game, F., van Netten, J. J., Apelqvist, J., Fitridge, R., Senneville, E., Schaper, N. C., & IWGDF Editorial Board
Venue
Diabetes/Metabolism Research and Reviews
Publisher
Wiley
Published
2023-05-14
Volume
40
Issue
3
Pages
e3656-e3656
ISSN
  • 1520-7552 (ISSN-L)
  • 1520-7560
OpenAlex
W4376598557
Cited by
27
References
10
FWCI
4.47
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.